Remimazolam Besylate Patent Expiration

Remimazolam Besylate is used for procedural sedation in adults undergoing short procedures. It was first introduced by Acacia Pharma Ltd in its drug Byfavo on Oct 6, 2020.


Remimazolam Besylate Patents

Given below is the list of patents protecting Remimazolam Besylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Byfavo US10052334 Dosing regimen for sedation with CNS 7056 (remimazolam) Nov 07, 2031 Acacia
Byfavo US10195210 Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov 07, 2031 Acacia
Byfavo US10342800 Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov 07, 2031 Acacia
Byfavo US10472365 Short-acting benzodiazepine salts and their polymorphic forms Jul 10, 2027 Acacia
Byfavo US10722522 Dosing regimen for sedation with CNS 7056 (remimazolam) Nov 07, 2031 Acacia
Byfavo US10961250 Short-acting benzodiazepine salts and their polymorphic forms Jul 10, 2027 Acacia
Byfavo US9561236 Dosing regimen for sedation with CNS 7056 (Remimazolam) Apr 30, 2033 Acacia
Byfavo US9737547 Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov 07, 2031 Acacia
Byfavo US9777007 Short-acting benzodiazepine salts and their polymorphic forms Jul 10, 2027 Acacia
Byfavo US9827251 Dosing regimen for sedation with CNS 7056 (remimazolam) Nov 07, 2031 Acacia
Byfavo US9914738 Short-acting benzodiazepine salts and their polymorphic forms Jul 10, 2027 Acacia


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳